Johnson & Johnson announced the launch of VARIPULSE Pro in Europe after getting CE Mark approval. This new device is part of their pulsed field ablation (PFA) products and is designed to make procedures faster and maintain safety and effectiveness.
VARIPULSE Pro uses a new pulse method that works at lower temperatures and is five times faster than the old version, while still creating the same results. It works with the CARTO 3 System for precise mapping and safe treatment.
The device is being studied in the VARIPURE follow-up study, and J&J will keep collecting clinical evidence as it is used commercially.
J&J will show VARIPULSE Pro at the European Heart Rhythm Association (EHRA) meeting, with live demos, hands-on training, and educational sessions. Early results from the ongoing VARIPURE study will also be presented.
According to coherent market insights, the Medical Devices Market is expected to grow at a CAGR of 7.3% during 2026 to 2033. Currently, the market is at USD 735.12 Bn in 2025 and is expected to be around USD 1,203.81 Bn by 2033. This significant growth is driven by the increasing demand for advanced healthcare solutions, rising prevalence of chronic diseases, and continuous innovation in medical technology.
“In our early experience, VARIPULSE Pro has been exceptionally smooth and easy to use,” said Tom De Potter5, M.D., Head of Electrophysiology and Associate Director of the Heart Center, OLV Hospital, Aalst, Belgium. “The speed is particularly striking and contributes to more efficient procedures without compromising precisionii. The integration with CARTO mapping and intracardiac echocardiography (ICE)facilitate accurate positioning and consistent lesion delivery4, contributing to a very positive procedural experience.”
“The introduction of VARIPULSE Pro in Europe reflects our commitment to advancing our PFA platforms through continuous innovation, enhancing procedural experience while maintaining the consistency and precision physicians expect from the VARIPULSE Platform,” said Michael Bodner, Company Group Chair, Electrophysiology & Neurovascular, MedTech, Johnson & Johnson. “This launch demonstrates our dedication to continuously evolving PFA technologies based on real-world learnings and our scientific expertise, supporting physicians to deliver high-quality care and improved patient outcomes.”
Source:
Newsroom: Johnson & Johnson
Company: Johnson & Johnson